Telemedicine Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioptigen
Bioptigen completes series A funding round, investment closes at $1.3 million
September 13th, 2006
Bioptigen, an optical technology company developing proprietary advances in the field of optical coherence tomography (OCT), announces the closing of its Series A round of funding.
The round closed at $1.3 million and investors included the Piedmont Angel Network, the Inception Micro-Angel Fund and qualified individuals. Bioptigen will be The Piedmont Angel Network's PAN Two Fund's first investment.
"We are exhilarated to have completed our first funding round with the support of the North Carolina angel investor community," stated Bioptigen's president and CEO Eric Buckland. "Over the past year, funded largely by phase I SBIR grants, we...
Source: Telemedicine Business Week (2006-09-13)
|
